In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $50.00. The company’s shares closed last Monday at $34.44, close to its 52-week low of $24.87.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 14.3% and a 35.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.
Currently, the analyst consensus on Arcturus Therapeutics is a Hold with an average price target of $38.17, which is a 15.8% upside from current levels. In a report issued on July 30, Chardan Capital also assigned a Hold rating to the stock.
The company has a one-year high of $129.71 and a one-year low of $24.87. Currently, Arcturus Therapeutics has an average volume of 490.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.